Discussion about this post

User's avatar
Brooks Leitner, MD, PhD's avatar

Very well said.

Our thesis is that functional physiological measures are under utilized in clinical trials.

High resolution molecular data ends up being anchored to reductionist clinical parameters (eg a metabolomic signature to predict biological age— what does age tell you about a person’s capabilities?)

Data sets that combine high resolution molecular information along with functional physiology (eg peak exercise capacity, insulin sensitivity via hyperinsulinemic euglycemic clamps) allow you to have meaningful functional benchmarks which you can anchor Omics to.

Would love to chat about some of the prospective clinical trials we are taking on

Alex Washburne's avatar

Biologist who did business intelligence at a hedge fund for nearly a decade here.

The data we buy in finance has a price tag weighed against the value of information it contains.

Biologists don’t often think of the value of information in financial terms, but this is crucial. In finance, we can ballpark the value of information based on the end result of the total volume of arbitrage opportunities (not just a % change, but actual number of dollars you could make trading on that info).

For bio, we’re not developing trading strategies but implicitly data drives decisions and so we need to refocus on the decisions. Are we making a diagnosis? Preparing medical managers for a surge of medical demand? Choosing a medicine with more specific estimation of safety and efficacy? Making decisions about warfighter behavioral/protocol changes in light of an outbreak in the unit? Making a new drug?

From a business intelligence perspective, the decisions we’re trying to make should inform the “request for data/information” phrased in terms of the quantity we’re trying to better estimate.

That can inform which data provides the valuable information, creating a better economic exchange of information on biological systems.

Ready for more?